Skip to main content

Table 2 Timing and dose at treatment discontinuation

From: Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

Dose of escitalopram Week of last completed visit Number of patients discontinued
   Due to an AEa Not due to an AEa
10 mg Week 0 (baseline) 6 0
  Week 8 1 0
20 mg Week 4 1 0
  Week 16 1 0
30 mg Week 8 1 0
35 mg Week 8 0 2 (1 - ineligible to continue, 1 - lack of efficacy)
40 mg Week 24 1 0
45 mg Week 24 1 1 (lack of efficacy)
50 mg Week 16 1 0
  Week 20 0 1 (lost to follow up)
  Week 24 0 1 (lack of efficacy)
  1. a AE: adverse event. The reason for withdrawal was taken from the End of Study Case Report Form (CRF) page. This stated that a patient withdrew due to an AE, although this was not recorded as a withdrawal as a result of an AE on the AE CRF page